[{"id":"b1fc3749-e95d-4a68-ab16-6259c58fc366","acronym":"","url":"https://clinicaltrials.gov/study/NCT05011097","created_at":"2021-08-18T14:53:35.366Z","updated_at":"2024-07-02T16:36:26.202Z","phase":"Phase 1","brief_title":"A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT05011097","lead_sponsor":"Wuhan YZY Biopharma Co., Ltd.","biomarkers":" IFNG • IL6 • TNFA • PTPRC • CD69 • IL2 • NCAM1 • IL10 • CD14 • IFNA1","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • PTPRC • CD69 • IL2 • NCAM1 • IL10 • CD14 • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Y150"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 07/08/2021","start_date":" 07/08/2021","primary_txt":" Primary completion: 07/30/2023","primary_completion_date":" 07/30/2023","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2021-08-18"}]